File Download
  Patent History
  • Application
    US 12/3035414 2011-02-25
  • Publication
    US 2011212181 2011-09-01

published patent: COMPOSITIONS AND METHODS FOR TREATING CHRONIC RESPIRATORY INFLAMMATION

TitleCOMPOSITIONS AND METHODS FOR TREATING CHRONIC RESPIRATORY INFLAMMATION
Priority Date2011-02-25 US 12/3035414
2010-02-26 US 12/308597P
Inventors
Issue Date2011
Citation
US Published patent application US 2011212181. Washington, DC: US Patent and Trademark Office (USPTO), 2011 How to Cite?
AbstractNeutrophil elastase (NE) is a protease secreted by neutrophils during inflammation. Aberrant expression of NE such as in chronic respiratory inflammatory diseases, results in tissue destruction and decline in lung function. Compositions including an NE-targeting agent that targets the pathologic elements of respiratory inflammation are provided. Non-anticoagulant heparin derivatives or fragments are exemplary NE-targeting agents. The compositions preferably include a carrier, such as chitosan, to facilitate delivery of the active agent. Methods of manufacturing non-anticoagulant heparin are also provided. Methods of administering the disclosed compositions to treat respiratory diseases are also disclosed. In preferred methods, an effective amount of the pharmaceutical composition is administered to subject in need thereof to reduce, inhibit, or alleviate one or more symptoms of chronic respiratory inflammation. In the most preferred embodiment, the composition is administered as a dry powder, intranasally or by inhalation.
Persistent Identifierhttp://hdl.handle.net/10722/177019

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:38:57Z-
dc.date.available2012-11-30T08:38:57Z-
dc.date.issued2011-
dc.identifier.citationUS Published patent application US 2011212181. Washington, DC: US Patent and Trademark Office (USPTO), 2011en_HK
dc.identifier.urihttp://hdl.handle.net/10722/177019-
dc.description.abstractNeutrophil elastase (NE) is a protease secreted by neutrophils during inflammation. Aberrant expression of NE such as in chronic respiratory inflammatory diseases, results in tissue destruction and decline in lung function. Compositions including an NE-targeting agent that targets the pathologic elements of respiratory inflammation are provided. Non-anticoagulant heparin derivatives or fragments are exemplary NE-targeting agents. The compositions preferably include a carrier, such as chitosan, to facilitate delivery of the active agent. Methods of manufacturing non-anticoagulant heparin are also provided. Methods of administering the disclosed compositions to treat respiratory diseases are also disclosed. In preferred methods, an effective amount of the pharmaceutical composition is administered to subject in need thereof to reduce, inhibit, or alleviate one or more symptoms of chronic respiratory inflammation. In the most preferred embodiment, the composition is administered as a dry powder, intranasally or by inhalation.en_HK
dc.titleCOMPOSITIONS AND METHODS FOR TREATING CHRONIC RESPIRATORY INFLAMMATIONen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorShum, DKYen_HK
dc.contributor.inventorIp, MSMen_HK
dc.contributor.inventorChan Chi Hangen_HK
dc.contributor.inventorLeung Valeria On Yueen_HK
patents.identifier.applicationUS 12/3035414en_HK
patents.description.assigneeUNIV HONG KONG [HK]en_HK
patents.description.countryUnited States of Americaen_HK
patents.date.publication2011-09-01en_HK
patents.identifier.hkutechidBioch-2009-00336-1-
patents.date.application2011-02-25en_HK
patents.date.priority2011-02-25 US 12/3035414en_HK
patents.date.priority2010-02-26 US 12/308597Pen_HK
patents.description.ccUSen_HK
patents.identifier.publicationUS 2011212181en_HK
patents.relation.familyUS 2011212181 (A1) 2011-09-01en_HK
patents.relation.familyWO 2011103774 (A1) 2011-09-01en_HK
patents.description.kindA1en_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats